Want to see BDSX full AI Analyst Report?
EarningsQ2 2026 Earnings Report
BDSX Q2 2026 EPS Results
Actual EPS-$0.71
Consensus EPS-$0.90
Beat/MissBeat by +$0.19
One Year Ago EPS-$1.60
BDSX Q2 2026 Revenue Results
Actual Revenue$26.86M
Expected Revenue$26.03M
Beat/MissBeat by +$835.00K
YoY Revenue Growth+34.18%
Earnings Announcement Details
QuarterQ2 2026
Date08/05/2026
TimeAfter Close
Conference CallWednesday, August 5, 2026
BDSX Upcoming Earnings
Biodesix's next earnings date is estimated for March 16, 2027, based on past reporting schedules.
Q2 2026 Earnings Call Audio
BDSX Q2 2026 Earnings Call
0:00 / 0:00
Q2 2026 Earnings Slide Deck
No slide deck is available for this earnings event.
Q2 2026 Earnings Call Summary
Earnings Call Sentiment|Positive
The call emphasized strong commercial momentum: high revenue growth (+34% YoY), accelerating test volumes (+38% YoY) driven by major PCP adoption (+133% YoY), improving ASPs, and sustained high gross margins (82%). Operational discipline produced improving profitability metrics (net loss and adjusted EBITDA materially improved YoY) and better cash consumption. Headwinds include continued net losses, lumpiness in development services revenue, operating expenses still slightly above quarterly revenue, and limited near-term margin upside. Management reiterated confident full-year revenue guidance ($108M–$114M), planned salesforce expansion to ~120 reps, and ongoing clinical evidence generation to support adoption. Overall, positive commercial and operational trends outweigh remaining challenges, indicating constructive progress toward profitability.Company Guidance
Strong Revenue Growth
Total revenue of $26.9M in Q2 2026, up 34% year-over-year, driven primarily by diagnostic testing growth.
Diagnostic Testing Expansion
Diagnostic testing revenue of $25.4M, a 42% increase YoY, supported by higher test volumes and improved average revenue per test (ASPs).
Accelerating Test Volumes
Total test volumes approximately 20,900, up 38% YoY; primary care volumes grew 133% YoY and pulmonology volumes grew 31% YoY, with PCP representing ~15% of volumes.
High and Improving Gross Margins
Gross margin of 82% in Q2, a 200 basis-point improvement YoY and the fifth consecutive quarter at or above 80%.
Operational Leverage and Controlled Expense Growth
Operating expenses (excluding direct costs) increased only 7% YoY to $27.4M while revenue grew 34%, reflecting expanding operating leverage amid commercial expansion.
Improved Profitability Metrics
Net loss narrowed to $7.3M (37% improvement YoY) and adjusted EBITDA loss improved to $3.2M (56% improvement YoY), indicating progress toward sustained profitability.
Stronger Cash Position and Lower Cash Burn
Ended quarter with $30M in unrestricted cash (up 17% sequentially, including $6.5M ATM proceeds). Excluding ATM proceeds, net cash used was $2.1M in the quarter versus $6.9M in Q2 2025 (70% improvement).
Commercial Scale and Hiring Plans
Average of 104 sales representatives in the field in Q2 with plan to end 2026 at ~120 reps; company expects continued sales productivity improvements and is maintaining a 6–8 hire per quarter cadence.
Clinical Evidence Driving Adoption
Publication demonstrating Nodify CDT can detect cancer in nodules as small as 4 mm (low false positive rate) and ATS presentations showing improved Stage 1 detection and real-world economic value; evidence driving increased Nodify orders and deeper account penetration.
Development Services Demand
Approximately $8.5M in contracted development services business, indicating ongoing external demand despite quarter-to-quarter timing variability.
BDSX Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed